Skip to content
DataLookout
Menu

PROTEA-PFONCT07172464

Early Feasibility Study (EFS) Evaluating Percutaneous Repair of the Atrial Septum With a Novel PFO Occluder: The PROTEA-PFO Study

StatusRecruiting
PhaseNot applicable
Primary completion (estimated)

At risk: Primary completion moved at least 11 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Aug 2026 to Aug 2027 Show 4 more changesShow less
    • Eligibility criteria expanded, about 9 words
    • Study completion pushed from Feb 2031 to Feb 2032
    • Study sites: 5 to 4
    • Secondary endpoints: details revised at 1 of 2 entries
  2. Notable Enrollment increased: 15 → 30 participants
    • Site details revised at 2 of 5 sites
    v4
  3. Minor Study sites: 4 to 5
    • Start date changed from estimate of Sep 2025 to Oct 9, 2025
    v3
  4. Minor Study sites: 3 to 4v2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Primary Safety Endpoint - Rate of Major Adverse Cardiovascular Events (MACE)
Timeframe: 30 days
Primary Performance Endpoint - Effective PFO Closure
Timeframe: 6 months

Secondary (2)

Secondary Safety Endpoints - Rate of device-related or procedure-related Serious Adverse Events (SAEs)
Secondary Performance Endpoint - Correct device position

Arms and interventions

Recross P3 Occluder (P3O) SystemExperimental

The Recross P3 Occluder (P3O) is being developed for the purpose of transcatheter closure of a patent foramen ovale (PFO) to reduce the risk of recurrent ischemic stroke in patients with PFO-associated stroke.

Devices: Recross P3 Occluder (P3O) System

Sites

4 sites in 1 country